Nikolai Püllen

Nikolai Püllen

Auto-generated profile, based on publicly available information

Nikolai Püllen

Department of Health Sciences and Technology, ETH Zürich, Zürich, Switzerland

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 October 2025 in Nature Chemical Biology
Verified
Journal Article
Open access
PDF file
VTVakil Takhaveev
Vakil Takhaveev
NPNikolai J. L. Püllen
Nikolai J. L. Püllen
NSNavnit K. Singh
Navnit K. Singh
LLLucie Lefevre
Lucie Lefevre
EAEmilie A. Aghajani
Emilie A. Aghajani
SSShana Sturla
Shana Sturla
DNA modifications drive aging, neurodegeneration, carcinogenesis and chemotherapy drug action. Accurate mapping of diverse DNA modifications with single-nucleotide precision in complex genomes remains challenging. We upgraded click-code-seq, a click-chemistry-aided DNA-modification mapping strategy, to enable its first application for sequencing oxidation and depurination in the human genome. We developed a companion fluorescence assay, click-fluoro-quant, to rapidly quantify common DNA modifications and novel adaptors to minimize false positives and assess modification frequency. We uncovered that endogenous DNA oxidation in a human cell line mirrors cancer mutational signatures linked to oxidative stress. The chemotherapy drug irofulven preferentially induces depurination in ApA dimers and promoters. Notably, oxidized guanines and apurinic sites, both irofulven induced and endogenous, are depleted in gene transcribed strands, with the strand bias increasing with gene expression. This work substantially advances click-code-seq for deciphering the impacts of key modifications in human DNA on cellular physiology and toxicological responses.



10 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKook Son
Kook Son
VTVakil Takhaveev
Vakil Takhaveev
VMVisesato Mor
Visesato Mor
HYHobin Yu
Hobin Yu
EDEmma Dillier
Emma Dillier
OSOrlando D. Schärer
Orlando D. Schärer
Most genotoxic anticancer agents fail in tumors with intact DNA repair. Therefore, trabectedin, a unique agent more toxic to cells with active DNA repair, specifically transcription-coupled nucleotide excision repair (TC-NER), provides new therapeutic opportunities. To unlock the potential of trabectedin and inform its application in precision oncology, a full mechanistic understanding of the drug’s TC-NER-dependent toxicity is needed. Here, we determined that abortive TC-NER of trabectedin-DNA adducts forms persistent single-strand breaks (SSBs) as the adducts block the second of the two sequential NER incisions. We mapped the 3’-hydroxyl groups of SSBs originating from the first NER incision at trabectedin lesions, recording TC-NER on a genome-wide scale. We showed that trabectedin-induced SSBs primarily occur in transcribed strands of active genes and peak near transcription start sites. Frequent SSBs were also found outside gene bodies, connecting TC-NER to divergent transcription from promoters. This work advances the use trabectedin for precision oncology and for studying TC-NER and transcription.